| Document |
Document Title |
|
WO/2015/177083A1 |
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar glif...
|
|
WO/2015/174695A1 |
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate...
|
|
WO/2015/170635A1 |
This non-ionic surfactant is characterized by being represented by general formula (1). (In general formula (1), R1 is a chain alkyl group optionally containing a branched chain, R2 is a hydrogen atom or an alkyl group, and R3 is a hydro...
|
|
WO/2015/163446A1 |
The present invention provides a method for producing an imidazole compound represented by formula (I) or a salt thereof, the method being characterized in comprising a step for reacting a compound represented by formula (II) or a salt t...
|
|
WO/2015/163817A1 |
A fluorophore or conjugated polymer with aggregation-induced emission characteristics useful for drug tracking and delivery, identification and labeling of biological subjects, such as cells or parts of a cell, as well as for imaging, an...
|
|
WO/2015/159103A1 |
Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are de...
|
|
WO/2015/159233A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan re...
|
|
WO/2015/158586A1 |
The present invention relates to a method for the production of 2-substituted 4-hydroxy-4-methyltetrahydropyrans from the acid-catalyzed reaction of 3-methylbut-3-ene-1-ol with an aldehyde, a stable odoriferous quality being achieved and...
|
|
WO/2015/158584A1 |
The invention relates to a method for producing 2-substituted 4-methyl-tetrahydropyrans of general formula (I) from starting materials containing at least one 2-substituted 4,4-dimethyl-1,3-dioxane of general formula (II).
|
|
WO/2015/158426A1 |
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis ...
|
|
WO/2015/158585A1 |
The invention relates to a method for producing 2-substituted 4-hydroxy-4-methyl-tetrahydropyrans of general formula (I) from starting materials which contain at least one 2-alkyl-4,4-dimethyl-1,3-dioxane of general formula (II).
|
|
WO/2015/156558A1 |
The present invention provides a novel 5,6-dihydroergosterol glycoside derivative. The novel 5,6-dihydroergosterol glycoside derivative according to the present invention can be usefully used as an agent for preventing or treating dermat...
|
|
WO/2015/153720A1 |
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
|
|
WO/2015/138969A1 |
Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subjec...
|
|
WO/2015/137289A1 |
The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-...
|
|
WO/2015/129412A1 |
Provided is a liquid crystalline compound that exhibits at least one physical property such as high stability to heat, light, or the like, a high clearing point, a low liquid crystal phase lower limit temperature, a low viscosity, suitab...
|
|
WO/2015/129832A1 |
The present invention is a radiosensitive resin composition containing: a polymer having a structural unit that contains the group represented by formula (1); and a radiosensitive acid generator. In formula (1), R1 is a substituted or un...
|
|
WO/2015/129860A1 |
The present invention provides a therapeutic agent useful in the treatment and/or prevention of conditions, including cancer, caused by enhanced OPN production, the therapeutic agent containing a compound represented by the formula (in t...
|
|
WO/2015/126936A1 |
The invention relates to substituted delta-lactones as well as to processes for synthesizing them, e.g., using fatty acids as starting material.
|
|
WO/2015/117538A1 |
The present invention relates to a new crystalline form of dapagliflozin represented by formula (I). The crystalline form has a characteristic absorption peak at about 4.318(20.45) in X-ray powder diffraction pattern shown by angle 2 the...
|
|
WO/2015/116786A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...
|
|
WO/2015/110370A1 |
The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or pi...
|
|
WO/2015/111529A1 |
Provided are: a near-infrared absorbing composition which provides a cured film that has high transmittance in the visible light region and exhibits high shielding performance in the near-infrared region; a near-infrared blocking filter;...
|
|
WO/2015/108136A1 |
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...
|
|
WO/2015/103510A1 |
Described are RORγ modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided...
|
|
WO/2015/103507A1 |
Described are RORϒ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...
|
|
WO/2015/103508A1 |
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...
|
|
WO/2015/089137A1 |
The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin inclu...
|
|
WO/2015/078802A1 |
The present invention relates to compounds of general formula (I), wherein the groups R1, R2, R3, X, m and n are defined as in claim 1, wich have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate ...
|
|
WO/2015/074135A1 |
The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates ...
|
|
WO/2015/052283A1 |
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-prolife...
|
|
WO/2015/049940A1 |
The present invention relates to a compound having a 2,6-difluorophenyl ether structure, which is useful as an organic electronic material or a medicinal or agrochemical agent, particularly a material for liquid crystal display elements....
|
|
WO/2015/044849A1 |
The present invention provides a process for the preparation of (1C)-2,3,4,6-tetra- O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D
-glucitol of Formula III. The invention also provides a process for the purification of dapa...
|
|
WO/2015/042397A1 |
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associat...
|
|
WO/2015/040571A1 |
The present invention provides an improved process for the preparation of dapagliflozin.of Formula (II) wherein the process comprises the step of hydrolyzing the compound of Formula (III) in the presence of an amine base.
|
|
WO/2015/032942A1 |
The invention relates to a compound of Formula (I) and its use as a selective dipeptidyl peptidase I inhibitor, as well as pharmaceutical compositions comprising said compound, and methods of treatment involving said compounds.
|
|
WO/2015/032943A1 |
The invention relates to compounds of Formula (I) and its use as a selective dipeptidyl peptidase I inhibitor, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.
|
|
WO/2015/032945A1 |
The invention relates to compounds of Formula (I) and their use as selective dipeptidyl peptidase I inhibitors, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.
|
|
WO/2015/032357A1 |
Zanamivir, a Zanamivir intermediate compound (formula 2), and a preparation method therefor. The preparation method is method 1 or 2. Method 1 comprises the following steps: compound 3 undergoes a reaction to remove a protecting group so...
|
|
WO/2015/031295A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2015/030189A1 |
Provided is a compound which exhibits bone formation acceleration activity (and/or bone resorption suppression activity). The compound is either a compound having a general formula (I) (wherein the substituents are as defined in the desc...
|
|
WO/2015/025859A1 |
A radiation-sensitive resin composition that comprises a polymer having an acid-dissociable group-containing structural unit, a compound comprising a radiolytic onium cation and a counter anion, and a solvent, wherein the counter anion h...
|
|
WO/2015/008779A1 |
The present invention relates to a compound represented by formula (I) (In the formula, Ar is a substituted or unsubstituted aromatic group, R is a substituted or unsubstituted hydrocarbon group, or a substituted or unsubstituted heteroc...
|
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2014/206349A1 |
The present invention relates to an oxa-thia-bicyclo[3.2.1]octane derivative, a preparation method, and use of same, and particularly to an oxa-thia-bicyclo[3.2.1]octane derivative represented by the general formula (I) or a hydrate, a s...
|
|
WO/2014/202168A1 |
Compounds of the formula I in which R1, R4, R6, R, X1, X2, X3, X4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, card...
|
|
WO/2014/197169A1 |
A method for protecting a phenol group on a precursor compound is provided. The method includes reacting the phenol group with dihydropyran in an acid catalyzed protection reaction and quenching the protection reaction with a strong base...
|
|
WO/2014/195553A1 |
The invention relates to a compound of formula (I), where R is selected from a methyl group or an ethyl group (I), the hydroxy acid forms of said compound, the pharmaceutically acceptable salts of said hydroxy acids, and pharmaceutically...
|
|
WO/2014/191535A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is fluorine or bromine; R2 is ethynyl, C1-C3alkoxy, C1-C3haloalkoxy, or C1-C3alkoxy-C1-C3alkoxy-; and Q is a pyran-3,5-dione-4-yl, a thiopyr...
|
|
WO/2014/191578A1 |
Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and...
|
